182 related articles for article (PubMed ID: 26340136)
1. Relationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancer.
Thor M; Olsson CE; Oh JH; Petersen SE; Alsadius D; Bentzen L; Pettersson N; Muren LP; Waldenström AC; Høyer M; Steineck G; Deasy JO
Acta Oncol; 2015; 54(9):1326-34. PubMed ID: 26340136
[TBL] [Abstract][Full Text] [Related]
2. Predictors of radiation-induced gastrointestinal morbidity: A prospective, longitudinal study following radiotherapy for carcinoma of the prostate.
Yeoh EK; Krol R; Dhillon VS; Botten R; Di Matteo A; Butters J; Brock AR; Esterman A; Salisbury C; Fenech M
Acta Oncol; 2016 May; 55(5):604-10. PubMed ID: 27046049
[TBL] [Abstract][Full Text] [Related]
3. Urinary bladder dose-response relationships for patient-reported genitourinary morbidity domains following prostate cancer radiotherapy.
Thor M; Olsson C; Oh JH; Petersen SE; Alsadius D; Bentzen L; Pettersson N; Muren LP; Høyer M; Steineck G; Deasy JO
Radiother Oncol; 2016 Apr; 119(1):117-22. PubMed ID: 26879287
[TBL] [Abstract][Full Text] [Related]
4. Spatial rectal dose/volume metrics predict patient-reported gastro-intestinal symptoms after radiotherapy for prostate cancer.
Casares-Magaz O; Muren LP; Moiseenko V; Petersen SE; Pettersson NJ; Høyer M; Deasy JO; Thor M
Acta Oncol; 2017 Nov; 56(11):1507-1513. PubMed ID: 28885095
[TBL] [Abstract][Full Text] [Related]
5. Mean absorbed dose to the anal-sphincter region and fecal leakage among irradiated prostate cancer survivors.
Alsadius D; Hedelin M; Lundstedt D; Pettersson N; Wilderäng U; Steineck G
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):e181-5. PubMed ID: 22677373
[TBL] [Abstract][Full Text] [Related]
6. Increased rectal wall stiffness after prostate radiotherapy: relation with fecal urgency.
Krol R; Hopman WP; Smeenk RJ; Van Lin EN
Neurogastroenterol Motil; 2012 Apr; 24(4):339-e166. PubMed ID: 22235913
[TBL] [Abstract][Full Text] [Related]
7. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
8. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
[TBL] [Abstract][Full Text] [Related]
9. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
Yeoh EE; Fraser RJ; McGowan RE; Botten RJ; Di Matteo AC; Roos DE; Penniment MG; Borg MF
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):943-55. PubMed ID: 12605972
[TBL] [Abstract][Full Text] [Related]
10. Toward a definition of a threshold for harmless doses to the anal-sphincter region and the rectum.
al-Abany M; Helgason AR; Cronqvist AK; Lind B; Mavroidis P; Wersäll P; Lind H; Qvanta E; Steineck G
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1035-44. PubMed ID: 15752882
[TBL] [Abstract][Full Text] [Related]
11. Dose-response relations for anal sphincter regarding fecal leakage and blood or phlegm in stools after radiotherapy for prostate cancer. Radiobiological study of 65 consecutive patients.
Mavroidis P; al-Abany M; Helgason AR; Agren Cronqvist AK; Wersäll P; Lind H; Qvanta E; Theodorou K; Kappas C; Lind BK; Steineck G; Brahme A
Strahlenther Onkol; 2005 May; 181(5):293-306. PubMed ID: 15900425
[TBL] [Abstract][Full Text] [Related]
12. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer.
Cheng JC; Schultheiss TE; Nguyen KH; Wong JY
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):351-7. PubMed ID: 18164841
[TBL] [Abstract][Full Text] [Related]
13. Differences in radiation dosimetry and anorectal function testing imply that anorectal symptoms may arise from different anatomic substrates.
Smeenk RJ; Hopman WP; Hoffmann AL; van Lin EN; Kaanders JH
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):145-52. PubMed ID: 20950951
[TBL] [Abstract][Full Text] [Related]
14. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
[TBL] [Abstract][Full Text] [Related]
15. Dose-effect relationships for individual pelvic floor muscles and anorectal complaints after prostate radiotherapy.
Smeenk RJ; Hoffmann AL; Hopman WP; van Lin EN; Kaanders JH
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):636-44. PubMed ID: 22137024
[TBL] [Abstract][Full Text] [Related]
16. Statistical analysis of dose-volume profiles and its implication for radiation therapy planning in prostate carcinoma.
Vanasek J; Odrazka K; Dolezel M; Kolarova I; Jarkovsky J; Pavlik T; Hlavka A; Dusek L
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):769-76. PubMed ID: 23628133
[TBL] [Abstract][Full Text] [Related]
17. Multivariate normal tissue complication probability modeling of gastrointestinal toxicity after external beam radiotherapy for localized prostate cancer.
Cella L; D'Avino V; Liuzzi R; Conson M; Doria F; Faiella A; Loffredo F; Salvatore M; Pacelli R
Radiat Oncol; 2013 Sep; 8():221. PubMed ID: 24053357
[TBL] [Abstract][Full Text] [Related]
18. Normal tissue complication probability (NTCP) models for late rectal bleeding, stool frequency and fecal incontinence after radiotherapy in prostate cancer patients.
Schaake W; van der Schaaf A; van Dijk LV; Bongaerts AH; van den Bergh AC; Langendijk JA
Radiother Oncol; 2016 Jun; 119(3):381-7. PubMed ID: 27157889
[TBL] [Abstract][Full Text] [Related]
19. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus.
Kalakota K; Liauw SL
Urology; 2013 Jun; 81(6):1196-201. PubMed ID: 23540863
[TBL] [Abstract][Full Text] [Related]
20. Avoidance of late rectal toxicity after high-dose-rate brachytherapy boost treatment for prostate cancer.
Kragelj B; Zlatic J; Zaletel-Kragelj L
Brachytherapy; 2017; 16(1):193-200. PubMed ID: 27908678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
